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Abstract: Increased cardiovascular morbidity and mortality in individuals with type 2 diabetes
(T2DM) is a significant clinical problem. Despite advancements in achieving good glycaemic con-
trol, this patient population remains susceptible to macrovascular complications. We previously
discovered that vascular smooth muscle cells (SMC) cultured from T2DM patients exhibit persistent
phenotypic aberrancies distinct from those of individuals without a diagnosis of T2DM. Notably,
persistently elevated expression levels of microRNA-145 co-exist with characteristics consistent with
aging, DNA damage and senescence. We hypothesised that increased expression of microRNA-145
plays a functional role in DNA damage signalling and subsequent cellular senescence specifically
in SMC cultured from the vasculature of T2DM patients. In this study, markers of DNA damage
and senescence were unambiguously and permanently elevated in native T2DM versus non-diabetic
(ND)-SMC. Exposure of ND cells to the DNA-damaging agent etoposide inflicted a senescent pheno-
type, increased expression of apical kinases of the DNA damage pathway and elevated expression
levels of microRNA-145. Overexpression of microRNA-145 in ND-SMC revealed evidence of func-
tional links between them; notably increased secretion of senescence-associated cytokines and chronic
activation of stress-activated intracellular signalling pathways, particularly the mitogen-activated
protein kinase, p38α. Exposure to conditioned media from microRNA-145 overexpressing cells
resulted in chronic p38α signalling in naïve cells, evidencing a paracrine induction and reinforcement
of cell senescence. We conclude that targeting of microRNA-145 may provide a route to novel inter-
ventions to eliminate DNA-damaged and senescent cells in the vasculature and to this end further
detailed studies are warranted.
Keywords: type 2 diabetes; saphenous vein; smooth muscle cells; DNA damage; senescence; mi-
croRNA; microRNA-145
1. Introduction
The mechanisms underlying increased risk of coronary heart disease (CHD) and
its attendant complications in Type 2 diabetes (T2DM) are poorly understood. T2DM
reportedly confers up to 15 years of aging [1] whilst chronological aging, characterised by
loss of replication-competent cells and DNA damage, is a major risk factor for CHD. It is
well known that overwhelming DNA damage triggers a permanent DNA damage response
(DDR) and consequent cellular senescence, a permanent arrest of cell proliferation that is a
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fundamental mechanism of aging that may also play a role in some of the cardiovascular
complications of T2DM [2].
Patients with significant CHD frequently require arterial reconstruction in the form
of coronary artery bypass grafting (CABG), which in individuals with diabetes is most
frequently performed using autologous saphenous vein (SV) grafts [3,4]. Phenotypic
modulation of the venous smooth muscle cells (SMC) is an important mechanism that
enables vein graft adaptation to an arterial environment. Indeed, effective integration to an
environment of increased flow and pressure early after implantation is a key determinant of
the long-term patency of SV grafts [5]. SMC are not terminally differentiated and it is their
ability to retain plasticity, i.e., to modulate their phenotype in response to environmental
cues, which is key to their role in maintaining vascular homeostasis. Our group previously
discovered a distinct and persistent aberrant phenotype, specifically in SV-SMC cultured
from T2DM patients compared with those cultured from age-matched non-diabetic (ND)
patients that persisted throughout passaging [6–8]. The enlarged, flattened morphology and
impaired proliferation of T2DM-SMC bore resemblance to those of aged, DNA damaged
and senescent cells. However, the deleterious effects of DNA damage, senescence and
subsequent acquisition of a senescence-associated secretory phenotype (SASP) in SV-SMC,
specifically in the setting of human T2DM, have not been explored.
More recently we pursued the notion that persistence of a T2DM SV-SMC phenotype
in long-term culture was suggestive of “metabolic memory” underpinned by an epigenetic
mechanism. Indeed, we demonstrated that this phenotype was driven by elevated expres-
sion levels of a specific SMC-enriched microRNA, miRNA-145 [8]. Some recent studies
have shown that miRNAs, short non-coding RNAs that are negative regulators of gene
expression, in addition to regulating a host of cellular functions, also play crucial roles
in cellular responses to DNA damage (reviewed in [9]). Dysregulated miRNAs are also
believed to contribute to accelerated aging syndromes [10] and some vascular patholo-
gies [11–13], yet little is known about any relationship between miRNAs, diabetes and
vascular SMC dysfunction. Lack of consistency among cell types has suggested that dys-
regulation of miRNAs after DNA damage is cell-type specific [14]. The persistent aberrant
phenotype and accompanying elevated levels of miRNA-145 that we regularly observe in
T2DM SV-SMC [8] led us to hypothesise that a miRNA-145-mediated mechanism underlies
defective DNA damage/repair pathways and subsequent cellular senescence, specifically
in this cell-type.
2. Materials and Methods
2.1. Smooth Muscle Cell (SMC) Culture
SMC were cultured as previously described [15] from explants of SV obtained from
non-diabetic patients (ND-SMC), or patients diagnosed with type 2 diabetes (T2DM-SMC)
receiving oral therapy either alone or with the addition of insulin. All patients were
undergoing elective CABG surgery at the Leeds General Infirmary or Nuffield Health Leeds
hospital and samples were collected with local ethical committee approval (CA01/040)
and informed, written patient consent. The study conformed to the principles outlined in
the Declaration of Helsinki. SV specimens from a total of 36 patients were used: 19 ND
(90% male, mean age 65.7 ± 2.2 years) and 17 T2DM (88% male, mean age 67.7 ± 2.7 years).
T2DM patients were all receiving oral therapy, alone or in combination with insulin. SMC
were cultured in DMEM containing 10% bovine FCS, 25 mmol/L glucose, 1% penicillin,
streptomycin, fungizone and 2 mmol/L glutamine (full growth medium; FGM) at 37 ◦C in
5% CO2 in air. All experiments were performed on cells between passages 3 to 6.
2.2. Senescence Associated β-Galactosidase Staining
SMC were seeded at a density of 75000/well in 6 well plates and cultured in FGM
for 48 h prior to fixation and staining using a commercial β-galactosidase assay (Cell
Signaling Technologies #9860, New England Biolabs, Ipswich, MA, USA), as described
previously [16]. Senescent cells were identified by formation of a blue precipitate at pH 6
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and senescence scores determined by counting the proportion of senescent cells contained
within 10 low power (×40) microscopic fields of view.
2.3. Quantitative Real-Time RT-PCR
Cellular RNA was extracted and cDNA prepared as previously described [17]. Real-
time RT-PCR was performed in triplicate using an Applied Biosystems 7500 Real-time PCR
system and Taqman Gene Expression Assays (Thermo-Fisher Scientific, Waltham, MA,
USA). Data are presented as percentage of endogenous control (GAPDH) expression using
the formula 2−∆CT × 100.
2.4. Apoptosis Assay
SMC were plated in FGM at a density of 3000/well in 96 well plates and incubated
overnight. Apoptosis assays were performed as previously described [16]. Briefly, cells
were treated with 5 µmol/L NucView™ 488 caspase-3 substrate (Biotium). Images were
obtained in phase contrast and fluorescence mode using a ×10 objective and an IncuCyte
FLR time-lapse fluorescence microscope (Essen Bioscience, Newark, CI, USA). After 24 h,
cells were stained with 1 µmol/L Vybrant DyeCycle Green® (Molecular Probes, Invitrogen,
Eugene, OR, USA) and an apoptosis index calculated using an inbuilt algorithm.
2.5. Immunocytochemistry
SMC cultured on glass coverslips were fixed in 4% PFA prior to immunostaining with
phospho-histone H2AX (γH2AX) antibody (Cell Signaling Technologies #2577, New Eng-
land Biolabs, Ipswich, MA, USA) as described previously [18]. Coverslips were mounted
using Prolong Gold antifade reagent containing DAPI (Thermo-Fisher Scientific, Waltham,
MA, USA) and imaged on a Zeiss 700 confocal microscope. Nuclear morphology was
examined in DAPI-stained cells at × 400 magnification and the proportion of cell nuclei
displaying DNA damage (blebbing or apoptotic nuclei) was quantified as the number of
γH2AX-positive nuclei (pink) relative to the total number of regular, ovoid nuclei (blue).
2.6. Enzyme Llinked Immunosorbent Assays (ELISA)
Cell culture supernatants were collected from SMC, snap frozen and stored at −80 ◦C.
Secretion of IL-6, IL-8 and MCP-1 was determined by ELISA (Quantikine, R&D Systems).
2.7. Cell Proliferation
Cells were seeded in 24-well plates at a density of 10,000 cells/well and triplicate
counts performed over a 7-day period using a haemocytometer and trypan blue exclusion,
as previously [6].
2.8. Immunoblotting
Whole cell homogenates were prepared and immunoblotted as described previ-
ously [17] using antibodies to p-p38 (#9215), total p38 (#9228), p-ERK (#9106), total ERK
(#4695), p-Akt (#4691), total Akt (#2920), IκB (#9242), p21 (#2947), p-p53 (ser15) (#9284) (all
Cell Signaling Technologies), with α-tubulin (ab8226; Abcam) as a loading control.
2.9. Quantification of miRNA-145 Levels
Total RNA samples were analysed by preparing specific RT reactions for U6 and
miRNA-145 using Taqman MicroRNA Assays (Applied Biosystems). Real-time RT-PCR
was performed in triplicate and data presented as percentage endogenous control (U6)
expression using the formula 2−∆CT × 100.
2.10. Inhibition of DDR Apical Kinases
Cells were seeded in FGM at 10,000 cells/well in 24 well plates, cultured overnight
and then serum-deprived for 72 h prior to re-addition of FGM plus inhibitors of ATM
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(KU55933, 10 µM), ATR (AZ20, 10 µM), DNA-PK (NU7026, 3 µM) (all Generon) or DMSO
vehicle.
2.11. siRNA Knockdown
SMC were transfected with siRNA to ATM, ATR, DNA-PK or scrambled control
(20 nM, ONTARGETplus siRNA, Dharmacon) using Lipofectamine 2000 reagent (Thermo
Fisher Scientific), according to the manufacturer’s instructions.
2.12. miRNA-145 Overexpression
Overexpression of miRNA-145 was achieved by transfecting SMC with 15 nM premiRNA-
145 or negative control (premiRNA–ve) as described previously [8].
2.13. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7 software. Data are pre-
sented as mean ± SEM with n representing the number of experiments performed on cells
from different patients. Data were tested for normality prior to log transformation and
analysis by paired or unpaired t-test, or one way ANOVA with Dunnett’s post hoc test, as
appropriate. p < 0.05 was considered significant.
All data are contained within the article and supporting information. Data are avail-
able upon request.
3. Results
3.1. Inherent Characteristics of Senescence and DNA Damage in Native SV-SMC
We previously reported impaired proliferation and an enlarged flattened morphology
characteristic of senescence, in SV-SMC cultured from T2DM patients [6] which persists in
culture and throughout passaging [8]. Given that there is no single and definitive hallmark
of senescence [19], we examined a number of additional endpoints. T2DM-SMC exhibited
significantly increased senescence-associated (SA) β-gal staining (Figure 1A), increased
expression of IL-1α mRNA (Figure 1B), and reduced expression of nuclear lamin B1 mRNA
(LMNB1) [20] (Figure 1C), relative to ND-SMC. No differences were observed in apoptosis
(caspase-3 fluorescence assay) (Figure 1D). In addition, a significantly increased frequency
of γH2AX positive nuclei, symbolic of double-stranded DNA breaks (Figure 1E) and
aberrant nuclear morphology (Figure 1F) in the T2DM cells was indicative of augmented
DNA damage. Expression of IL-8 mRNA, an inflammatory mediator associated with SASP,
was elevated; however additional SASP mediators IL-6 and MCP-1 were unchanged at
the mRNA level (Figure 1G–I). Secretion of IL-6, IL-8 and MCP-1 from native ND and
T2DM-SMC was not significantly different but considerable variability between patients
was observed, independent of diabetic status (Supplementary Figure S1). These data
provide evidence that SV-SMC cultured from patients with T2DM exhibit inherently higher
levels of senescence and DNA damage than those of ND patients.




Figure 1. T2DM-SMC exhibit senescent features. (a) SMC were cultured in full growth medium for 48 h, fixed and stained 
for senescence-associated β-galactosidase (blue precipitate, scale bar = 200 μm, n = 7). (b) RNA was extracted from cells 
cultured for 24 h and expression of senescence-associated markers IL-1α and (c) LMNB1 measured by RT-PCR (n = 8). (d) 
SMC were cultured in full growth medium for 48 h, fixed and incubated with NucView 488 caspase 3 substrate (to indicate 
apoptotic cells, n = 4), (e) stained for early DNA damage marker γH2AX (pink foci, scale bar = 100 μm, n = 8), and (f) DAPI 
to visualise aberrant nuclei (denoted by asterisk, scale bar = 50 μm, n = 8). Basal expression of senescence-associated in-
flammatory genes (g) IL-6, (h) IL-8 and (i) MCP-1 was measured using RT-PCR (all n = 8). 
3.2. DNA Damage and DDR Pathway Activation in SV-SMC 
We next examined whether DNA damage alone could drive the acquisition of a 
T2DM-SMC phenotype in ND-SMC. Exposure to environmental stresses induces activa-
tion of the DDR signalling pathway, a cascade of kinase activations which culminate in 
cell cycle arrest to enable DNA repair. Phosphorylation of apical kinases ATM (ataxia-
telangiectasia mutated), ATR (ATM- and Rad3-Related) and/or DNA-PK (DNA-depend-
ent protein kinase catalytic subunit), depending on the type of DNA damage, activates 
multiple downstream events that lead to phosphorylation of H2AX (γH2AX) and the tu-
mour suppressor gene p53, and expression of the cell cycle inhibitor p21 that confers 
growth arrest (Figure 2A). 
Figure 1. T2DM-SMC exhibit senescent features. (a) SMC were cultured in full growth medium for 48 h, fixed and stained
for senescence-associated β-galactosidase (blue precipitate, scale bar = 200 µm, n = 7). (b) RNA was extracted from cells
cultured for 24 h and expression of senescence-associated markers IL-1α and (c) LMNB1 measured by RT-PCR (n = 8).
(d) SMC were cultured in full growth edium for 48 h, fixed and incubated with NucView 488 caspase 3 substrate (to
indicate apoptotic cells, n = 4), (e) stained for early DNA damage marker γH2AX (pink foci, scale bar = 100 µm, n = 8), and
(f) DAPI to visualise aberrant nuclei (denoted by asterisk, scale bar = 50 µm, n = 8). Basal expression of senescence-associated
inflammatory genes (g) IL-6, (h) IL-8 and (i) MCP-1 was measured using RT-PCR (all n = 8).
3.2. DNA Damage and DDR Pathway Activation in SV-SMC
We next examined whether DNA damage alone could drive the acquisition of a T2DM-
SMC phenotype in ND-SMC. Exposure to environmental stresses induces activation of
the DDR signalling pathway, a cascade of kinase activations which culminate in cell cycle
arrest to enable DNA repair. Phosphorylation of apical kinases ATM (ataxia-telangiectasia
mutated), ATR (ATM- and Rad3-Related) and/or DNA-PK (DNA-dependent protein kinase
catalytic subunit), depending on the type of DNA damage, activates multiple downstream
events that lead to phosphorylation of H2AX (γH2AX) and the tumour suppressor gene
p53, and expression of the cell cycle inhibitor p21 that confers growth arrest (Figure 2A).
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Figure 2. DNA damage drives a senescent SMC phenotype. (a) The DNA damage signalling pathway leading to phos-
phorylation of p53, and subsequent downstream effects. (b) SMC were treated with DNA-damaging agent etoposide (5 
μM) or vehicle control (DMSO) for up to 7 days and proliferation quantified by cell counting (n = 7). (c) The impact of 
etoposide on p53 phosphorylation was monitored using Western blotting after 24 h (n = 4). (d) The effect of DNA damage 
on apical kinase expression was explored in ND-SMC that were treated with 5 μM etoposide for 24 h. The expression of 
ATM, (e) ATR, (f) DNA-PK and (g) p21 was quantified using RT-PCR. The expression of these kinases was also measured 
in untreated T2DM-SMC to determine whether DNA damage per se could mimic a T2DM-SMC phenotype (all n = 8). (h) 
Cells were treated with etoposide for 24 h and then placed into FGM for 72 h. Cells were stained with SA-β-galactosidase 
(scale bar = 100 μm). (i) The influence of etoposide on expression of IL-1α, (j) LMNB1 (both n = 8) and (k) miRNA-145 
expression (n = 6–8) was quantified using RT-PCR. 
Figure 2. DNA damage drives a senescent SMC phenotype. (a) The A damage signalling pathway leading to phos-
phorylati n of p53, and sub equent downstream ef ects. (b) SMC w re treated with DNA-damaging agent etoposide
(5 µM) or vehicle control (DMSO) for up to 7 days and proliferation quantified by cell counting (n = 7). (c) The impact of
etoposide on p53 phosphorylation was monitored using Western blotting after 24 h (n = 4). (d) The effect of DNA damage
on apical kinase expression was explored in ND-SMC that were treated with 5 µM etoposide for 24 h. The expression of
ATM, (e) ATR, (f) DNA-PK and (g) p21 was quantified using RT-PCR. The expression of these kinases was also measured
in untreated T2DM-SMC to determine whether DNA damage per se could mimic a T2DM-SMC phenotype (all n = 8).
(h) Cells were treated with etoposide for 24 h and then placed into FGM for 72 h. Cells were stained with SA-β-galactosidase
(scale bar = 100 µm). (i) The influence of etoposide on expression of IL-1α, (j) LMNB1 (both n = 8) and (k) miRNA-145
expression (n = 6–8) was quantified using RT-PCR.
DNA damage was induced in ND-SMC using the chemotherapeutic agent etopo-
side (Sigma-Aldrich), which led to a marked reduction in cell proliferation (Figure 2B)
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and increased phosphorylation of p53 (Figure 2C). Whilst ATM and ATR mRNA were
expressed basally at higher levels in T2DM-SMC than in ND cells, exposure of ND cells
to etoposide induced increases in both ATM and ATR mRNA, comparable to the levels
of expression in native T2DM-SMC (Figure 2D,E). Conversely, DNA-PK did not differ
between ND and T2DM-SMC and etoposide treatment caused a reduction in DNA-PK ex-
pression (Figure 2F). Basal gene expression of p21 was inherently higher in T2DM cells and
etoposide treatment of ND cells led to a marked increase in p21 mRNA levels (Figure 2G).
Markers of senescence, namely increased SA β-gal staining (Figure 2H), increased IL-1α
mRNA expression (Figure 2I) and reduced LMNB1 mRNA expression (Figure 2J), were
observed in ND-SMC in response to etoposide, consistent with features detected in native
T2DM-SMC (Figure 1A–C). Finally, ND-SMC treated with etoposide exhibited a 1.5-fold
increase in miRNA-145 expression (Figure 2K), consistent with differences we previously
reported between native ND- and T2DM-SMC in a cohort of 130 patients [8]. miRNA-145
expression was also induced by oxidative stress, a more physiologically relevant stimulus
(Supplementary Figure S2).
3.3. Pharmacological Inhibition of DDR Kinases
To examine whether elevated DDR expression was responsible for the T2DM-SMC
phenotype, we employed a pharmacological approach in ND-SMC to investigate the effect
of apical kinase inhibition on SMC proliferation. Whilst inhibition of ATM (KU55933) or
DNA-PK (NU7026) did not modulate proliferation (Figure 3A–C), ATR inhibition (AZ20)
completely abolished any increase in cell number over a 7-day period (Figure 3B). miRNA-
145 expression was unaffected by any of the inhibitors (Figure 3D). Surprisingly, inhibition
of ATM or ATR increased ATM mRNA expression (Figure 3E). None of the three inhibitors
affected ATR mRNA expression levels (Figure 3F) and inhibition of ATM significantly
increased DNA-PK gene expression by 23% (Figure 3G). Inhibition of ATR suggested a
possible trend to increased p21 mRNA expression (Figure 3H).
3.4. siRNA Knockdown of DDR Kinases
To confirm these pharmacological data, we employed a gene-silencing approach to
individually knock down ATM, ATR and DNA-PK. siRNA inhibition caused selective
and specific reduction of each target mRNA within 24 h and was maintained for at least
96 h (Supplementary Figure S3). Anti-proliferative effects were comparable with pharma-
cological inhibition, specifically that ATM and DNA-PK knockdown did not modulate
SMC proliferation (Figure 4A–C) whilst ATR knockdown led to a significant reduction
in cell number (Figure 4B). As with pharmacological inhibition, miRNA-145 expression
was unaffected by ATM, ATR or DNA-PK knockdown (Figure 4D). Notably, the gene
silencing approach enabled selective inhibition of each kinase, without off-target effects on
the others (Figure 4E–G). In agreement with the pharmacological inhibition data, the effect
of ATR knockdown on p21 expression was again negligible, although increased p21 mRNA
expression was observed as a result of DNA-PK silencing (Figure 4H).
3.5. miRNA-145 Overexpression Modulates DNA Damage Signalling and Senescence
To determine whether miRNA-145 was upstream or downstream of DDR, ND-SMC
were transfected with premiRNA –ve (negative control) or premiRNA-145 (overexpression)
and parameters pertinent to the DNA damage pathway were evaluated. PremiR-145
transfection led to a marked overexpression as expected (Supplementary Figure S4) which
remained elevated for ≥7 days. Overexpression of miRNA-145 led to increased SA β-
gal 96 h post transfection (Figure 5A), although differences in γH2AX foci were less
evident (p = 0.08, Figure 5B). In contrast to increased IL-1α and reduced LMNB1 gene
expression observed in native T2DM cells, the opposite was observed in miRNA-145
overexpressing cells; reduced IL-1α mRNA and increased LMNB1 mRNA (Figure 5C,D).
With respect to apical kinases, whilst no consistent differences in ATM gene expression
were observed (Figure 5E), increased mRNA expression of ATR (Figure 5F) and decreased
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mRNA expression of DNA-PK (Figure 5G) were clear. Changes in p21 expression following
miRNA-145 transfection were inconsistent (Figure 5H). Importantly, secreted levels of
IL-6 (52% increase; Figure 5I), IL-8 (99% increase; Figure 5J) and MCP-1 (674% increase;
Figure 5K) 96 h after miRNA-145 transfection were unequivocally higher.




Figure 3. Pharmacological inhibition of apical kinases of the DNA damage response pathway modulates proliferation and 
gene expression. (a) SMC were treated with ATM inhibitor (KU55933; 10 μM), (b) ATR inhibitor (AZ20; 10 μM) or (c) 
DNA-PK inhibitor (NU7026; 3 μM) for up to 7 days and cell counts performed on days 0, 2, 4 and 7 (n = 4). After 72 h, 
RNA was extracted and the effect of all inhibitors on expression of (d) miRNA-145, (e) ATM, (f) ATR, (g) DNA-PK and (h) 
p21 was measured using RT-PCR (all n = 6). ns = non-significant. 
3.4. siRNA Knockdown of DDR Kinases 
To confirm these pharmacological data, we employed a gene-silencing approach to 
individually knock down ATM, ATR and DNA-PK. siRNA inhibition caused selective 
and specific reduction of each target mRNA within 24 h and was maintained for at least 
96 h (Supplementary Figure S3). Anti-proliferative effects were comparable with pharma-
cological inhibition, specifically that ATM and DNA-PK knockdown did not modulate 
SMC proliferation (Figure 4A–C) whilst ATR knockdown led to a significant reduction in 
cell number (Figure 4B). As with pharmacological inhibition, miRNA-145 expression was 
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ing approach enabled selective inhibition of each kinase, without off-target effects on the 
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Figure 3. Pharmacological inhibition of apical kinases of the DNA damage response pathway modulates proliferation
and gene expression. (a) SMC were treated with ATM inhibitor (KU55933; 10 µM), (b) ATR inhibitor (AZ20; 10 µM) or
(c) DNA-PK inhibitor (NU7026; 3 µM) for up to 7 days and cell counts performed on days 0, 2, 4 and 7 (n = 4). After 72 h,
RNA was extracted and the effect of all inhibitors on expression of (d) miRNA-145, (e) ATM, (f) ATR, (g) DNA-PK and
(h) p21 was measured using RT-PCR (all n = 6). ns = non-significant.
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3.6. Chronic Signalling Pathway Activation in miRNA-145-Overexpressing SMC
Persistently el vated l vels of miRNA-145 in T2DM-SMC may drive chronic stress
signalling to reduce proliferat on. To this end we explo ed activation of four intracellular
signalling pathways, p38MAPK, ERK, PI3K/Akt nd NF- κB. Cell lysates were prepared
from ND-SMC transfected 96 h ea lier with premiRNA-145 or r iRNA –ve (Figure 6A).
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independen of altered p38 protein expression (Figure 6B). Increased ERK phosphorylat on
was accompanied by increased to al protein l vels (Figure 6C). miRNA-145 over xpression
did not l ad to changes in Akt phosphorylation or expression (Figure 6D) whereas IκB
lev ls increased (Figure 6E), indicating re uced NF-κB pathway signalling. Finally, p21
protein expression wa i creased in respons to miRNA-145 overexpressio (Figure 6F).




Figure 5. Effect of miRNA-145 overexpression on SMC senescence, DDR signalling and SASP. ND-SMC were transfected 
with premiRNA-145 or premiRNA -ve. (a) After 4 days in full growth media, cells were fixed and stained for SA-β-galac-
tosidase (scale bar = 200 μM, n = 6). (b) IL-1α and (c) LMNB1 expression were measured by RT-PCR after 72 h (n = 7). (d) 
Cells were treated as (a) and stained for γH2AX (pink foci, scale bar = 100 μM, n = 6). (e) Expression levels of ATM, (f) 
Figure 5. Effect of miRNA-145 overexpression on SMC senescence, DDR signalling and SASP. ND-SMC were transfected
with premiRNA-145 or premiRNA -ve. (a) After 4 days in full growth media, cells were fixed and stained for SA-β-
galactosidase (scale bar = 200 µM, n = 6). (b) IL-1α and (c) LMNB1 expression were measured by RT-PCR after 72 h (n = 7).
(d) Cells were treated as (a) and stained for γ 2AX (pink foci, scale bar = 100 µM, n = 6). (e) Expression levels of ATM,
(f) ATR, (g) DNA-PK and (h) p21 were quantified by RT-PCR 72 h after miRNA-145 transfection (n = 7). (i) Protein secretion
of IL-6, (j) IL-8 and (k) MCP-1 was measured by ELISA after 96 h (n = 11).
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were serum-starved for 72 h prior t exposure to conditioned ( . S) medium harv sted from cells transfected with
premiRNA-145 or premiRNA -ve for 96 h. Protein lysates were immunoblotted for (b) p38, (c) ERK, (d) Akt (all expression
and phosphorylation), (e) IκB, (f) p21 expression. Phosphorylation of proteins was measured against expression of the
same protein, whereas changes in expression only were measured against α-tubulin as a loading control (n = 6–9). (g) Cells
were serum starved for 72hrs prior to exposure to conditioned (0.4% FCS) medium harvested from cells transfected with
premiRNA-145 or premiRNA -ve for 96 h. Cell counts were performed at 48 and 96h post exposure to determine cell number
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Proliferation assays were performed over 4 days by exposing serum-starved naïve
cells to CM from premiRNA –ve or premiRNA-145 transfected cells. Whilst control cells
remained viable, they did not proliferate, however significant cell loss was observed in
SMC exposed to CM collected from miRNA-145 overexpressing cells (Figure 7G). Both
populations exhibited substantial, yet comparable degrees of senescence (Figure 7H).
4. Discussion
We previously discovered that saphenous vein SMC (SV-SMC) cultured from patients
with T2DM displayed a persistent enlarged, flattened morphology with impaired prolifera-
tion [6] and that this was driven by an epigenetic mechanism involving elevated expression
of miRNA-145 [8]. Epigenetic changes are not uniquely attributable to microRNAs but
are regulated by other mechanisms, for example histone modifications and altered DNA
methylation/acetylation. We propose that the acquired phenotype in human T2DM -SMC
is very likely to also involve some of these epigenetic modifications, as has been reported
recently in aneurysm disease [21]. We have previously explored DNA modifications in
the miR-145 promoter although the data were inconclusive; further research is required
using cells from larger number of patients [22]. Notwithstanding, we demonstrated conclu-
sively that miRNA-145 is a critical regulator of phenotypic switching in human SV-SMC
in T2DM [8]. MiRNA-145 is endorsed as a master regulator of SMC behaviour [23] and
importantly has been identified as a tumour suppressor miRNA, confirming an association
with DNA damage in a variety of cancer cell-types [24,25].
The average age of the ND and T2DM patient cohorts in the current study was in
agreement with our previous report [8]; it was therefore unsurprising to reveal evidence of
cellular aging in both patient populations. However, T2DM-SMC cells were unequivocally
distinct from ND cells, lending weight to the idea that additional mechanisms conferring
accelerated aging and senescence in T2DM may be responsible. In support of this hy-
pothesis, we recently demonstrated in cultured human SMC of both aortic and venous
origin that miRNA-145 expression levels did not correlate with chronological age but
were elevated in abdominal aortic aneurysm SMC; a disorder associated with accelerated
vascular aging [18].
We proceeded to explore components of the DDR and confirmed that T2DM-SMC
exhibited persistent senescence and DNA damage evidenced by aberrant cell nuclei, in-
creased phosphorylation of H2AX and increased gene expression of ATM, ATR and p21.
Whilst higher mRNA expression levels of IL-8 suggested a developing SASP, this was
not corroborated by IL-6 or MCP-1 mRNA expression, or increased protein secretion
suggesting that T2DM-SMC had become senescent without progressing to the secretory
phenotype [26,27]. It was therefore logical to explore whether inflicting DNA damage
per se in ND-SMC could drive the acquisition of a native T2DM-SMC phenotype. In
doing so, we confirmed comparable changes in proliferation, senescence, apical kinase and
miRNA-145 gene expression. Taken together, our data indicate that T2DM-SMC exhibit
enhanced DNA damage and senescence and that stimulating DNA damage in ND-SMC
creates these features that are characteristic of T2DM-SMC. Our findings concur with a very
recent study in which DNA damage and senescence in venous SMC was higher in T2DM
versus ND patients who underwent lower limb amputation [28]. The authors revealed
that the observed enhanced DNA damage in the vasculature of T2DM patients plays an
important role in venous SMC calcification.
The primary inducers of the DDR signalling cascade are the ATR and ATM kinases,
which are generally activated in response to single strand and double strand DNA breaks,
respectively (reviewed in [29]). A third member of the family, DNA-PK, is a key component
of the non-homologous end joining process that repairs double strand DNA breaks [29].
Whilst we discovered that ATM and ATR (bot not DNA-PK) were significantly elevated
in T2DM-SMC, pharmacological and siRNA-mediated modulation revealed that it was
only inhibition of ATR (single strand DNA breaks) that led to reduced SV-SMC prolif-
eration. This unanticipated reduction in cell number is not without precedent and has
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previously been documented in a variety of cancer cell lines; reportedly by inducing apop-
tosis [30]. The reduction in cell number that we observed in proliferation assays may be
reflective of enhanced apoptosis rather than impaired proliferation, although this was
not evaluated. Nevertheless, neither pharmacological nor gene-silencing approaches to
apical kinase inhibition modulated miRNA-145 expression, suggesting that the aberrant
miRNA-145 expression was not directly driven by apical kinase activity and its effect on
reducing cell number is mediated via an alternate mechanism. Factors within the diabetic
milieu (and molecular changes within the diabetic SMC itself) are complex and involve
crosstalk between multiple pathways that include but are not limited to, apical kinase
expression/activity. Whilst DNA damage itself can induce miR-145 (Figure 7), we also
know that other pathways, for example we previously revealed TGF-β signalling [8], which
could theoretically have a greater impact on proliferation than apical kinase inhibition.
The current study has emphasized the limitations of relying on gene expression
studies only. Ideally, protein levels should be evaluated although in our hands, this was
not possible due to unreliable detection of the high molecular weight apical kinases. We
propose that the future development of kinase activity assays would be both reliable and
quantifiable.
Whilst accumulating evidence supports the idea that miRNAs may be novel players
in the DDR [9], a functional link between miRNA-145, SMC senescence and T2DM has not
been established until now. Overexpression of miRNA-145 increased β-galactosidase to
levels comparable with those in native T2DM cells whilst expression patterns of IL-1α were
not altered and LMNB1 was significantly increased, contrary to the reduction observed in
native T2DM cells. However, published reports are at variance, for example knockdown
of LMNB1 in mouse embryonic fibroblasts reduced miRNA-145 levels [31], whilst overex-
pression of miRNA-145 led to a reduction in LMNB1 in mesothelioma cells [32] but not
in rat cardiac myocytes [33]. Thus, the increased LMNB1 expression that we observed in
miRNA-145 overexpressing SV-SMC may not be involved in induction of senescence.
With respect to evidence for SASP, miRNA-145 overexpressing cells secreted signif-
icantly higher levels of IL-6, IL-8 and MCP-1, supporting the idea that miRNA-145 may
propagate senescence in SV-SMC via autocrine or paracrine mechanisms. In contrast, a role
for miRNA-145 in the initiation of DNA damage was not confirmed in terms of changes in
γH2AX, ATM and p21, although elevation of ATR mRNA was significant, akin to native
T2DM-SMC. Taken together, these data suggest that miRNA-145 lies downstream of the
initiation of DNA damage and plays a key role in provoking/reinforcing senescence.
Whilst the DDR pathway is rapid, development of SASP is a delayed and often
prolonged event over days or weeks [34,35], inferring that canonical DDR signalling is
insufficient to drive SASP and that additional molecular mechanisms are necessary. Notably,
the p38 MAPK pathway has been shown to be a signalling target of a variety of cellular
stresses–oxidative, metabolic, DNA damage and mechanical damage [34]. Importantly, p38
sustains SASP in cancer cells and tumorigenesis [36] and has been described as a marker of
vascular SMC senescence [27].
Our studies revealed chronic activation of p38α in miRNA-145 overexpressing cells.
A complex, bi-directional relationship between miRNA-145 and p38 appears to exist. For
example, p38 phosphorylation was suppressed by miRNA-145 in placental tissue [37],
yet in a different study an increase in p38 phosphorylation was noted on overexpression
and knockdown of miRNA-145 in chondrocytes [38]. A p38 response element has been
identified within the promoter of miRNA-145 [39,40], and p38 increased the processing of
pri-miRNA-145 to mature miRNA-145 [41].
We also observed increased ERK1/2 phosphorylation that was accompanied by in-
creased ERK protein expression. The relationship between miRNA-145 and ERK1/2 in
general appears to be inverse; indeed ERK1/2 inhibited miRNA-145 expression in hu-
man aortic SMC [42] and miRNA-145 inhibition reportedly enhanced ERK1/2 and Akt
phosphorylation in cancer cells [43]. Conversely, we observed a positive relationship
between miRNA-145 and ERK1/2 which might be indicative of a negative feedback mech-
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anism. Similarly, the observed increase in the anti-inflammatory protein IκB may be a
compensatory mechanism by the cell to ameliorate stress signalling. Taken together, these
observations provide evidence of chronic stress in miRNA-145 overexpressing SV-SMC.
p21 is a key downstream effector of p53 in the DDR pathway, halting the cell cycle to
allow DNA damage to be repaired [44]. We observed significantly elevated p21 expression
in native T2DM cells which was mimicked by inducing DNA damage or over-expressing
miRNA-145. This is in keeping with reduced proliferation in T2DM and miRNA-145
over-expressing cells, and concurs with previous literature where miRNA-145 and p53
have a complementary positive feedback relationship that increases p21 expression [45].
Factors released from senescent cells can inflict an autocrine or paracrine response
in neighbouring cells, known as a bystander effect [46], that can further reinforce DNA
damage and senescence. We showed that activation of p38 and expression of p21 were
analogous to that observed in “donor” miRNA-145 overexpressing cells, suggesting that
these signalling events are important for both induction and propagation of DNA damage
and cellular senescence.
5. Conclusions
In summary, emerging evidence supports a role for epigenetics in VSMC senescence
and aging and in particular, proposed functions for miRNAs [reviewed in [21]]. Induction
and progression of vascular pathophysiological states is multifactorial. Whilst SMC plastic-
ity is central to both adaptive (physiological) and adverse (pathological) remodelling [47],
aging and senescence are singularly detrimental. Importantly, we have identified a novel
mechanism linking aberrant miRNA-145 expression to SV-SMC senescence in the setting
of macrovascular complications of T2DM. Figure 8 provides an illustrative summary of
our findings. Succinctly, miRNA-145 drives increased senescence, reduced cell prolifer-
ation and activation of chronic stress signalling in response to DNA damage although
its potential to instigate DNA damage may be secondary to these important aspects. A
next logical step would be to explore whether gene silencing in native T2DM-SMC can
ameliorate miR-145-driven adverse cellular mechanisms that might delay vascular decline
in the setting of vein graft failure.
Whilst the use of 2D cell cultures is ideal for exploring mechanistic aspects, one of the
limitations is that other contributing factors that are active in intact tissues and organisms
are not considered. Our laboratory has a track record of expertise in the use of saphenous
vein organ cultures where the effect of other cell types (particularly the endothelium) and
extracellular matrix components in situ can also be considered [48]. Future studies will
explore such interactions and their functional outcomes.
Cells 2021, 10, 919 16 of 19




Figure 8. Summary of the central role for miRNA-145 in influencing SV-SMC DNA damage, proliferation and senescence. 
DNA damage upregulates expression of miRNA-145 in addition to inducing cell cycle arrest (p21 and p53 phosphoryla-
tion), upregulating apical kinase expression (ATR, ATM, DNA-PK) and cellular senescence (IL-1α, Lamin B1 and SA β-
gal. miRNA-145 reinforces DDR by also upregulating ATR expression, triggering intracellular kinase cascades (IκB, p38α, 
ERK) and inducing components of SASP (MCP-1, IL-6, IL-8). This induction of senescence and SASP inflicts a paracrine 
bystander effect on neighbouring cells through chronic activation of Akt and p38α, which can block cellular proliferation 
and perpetuate the T2DM-SMC phenotype. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: 
Secretion of senescence-associated inflammatory cytokines. Figure S2: Stimulation of miR-145 by 
oxidative stress. Figure S3: siRNA knockdown of ATM, ATR and DNA-PK has a prolonged inhibi-
tion on mRNA levels. Figure S4: PremiR-145 induces expression of miR-145. 
Author Contributions: Conceptualization, K.E.P. and N.A.T.; methodology, K.E.H., K.R.-S., 
M.A.B.; validation, K.E.H., K.R.-S. and M.A.B.; formal analysis, K.E.H. and K.R.-S.; investigation, 
K.E.H., K.R.-S., M.A.B., N.A.T., K.E.P.; resources, D.J.O., K.E.P.; writing—original draft prepara-
tion, K.E.P., K.R.-S., N.A.T., K.E.H.; writing—review and editing, M.A.B., D.J.O.; supervision, 
Figure 8. Summary of the central role for miRNA-145 in influencing SV-SMC DNA damage, proliferation and senescence.
DNA damage upregulates expression of miRNA-145 in addition to inducing cell cycle arrest (p21 and p53 phosphorylation),
upregulating apical kinase expression (ATR, ATM, DNA-PK) and cellular senescence (IL-1α, Lamin B1 and SA β-gal.
miRNA-145 reinforces DDR by also upregulating ATR expression, triggering intra llul r kinase cascades (IκB, p38α,
ERK) and inducing components of SASP (MCP-1, IL-6, IL-8). This induction of senescence and SASP inflicts a paracrine
bystander effect on neighbouring cells through chronic activation of Akt and p38α, which can block cellular proliferation
and perpetuate the T2DM-SMC phenotype.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10040919/s1, Figure S1: Secretion of enescence-associated inflammatory cytokines.
Figure S2: Stimulation of miR-145 by oxidative stress. Figure S3: siRNA knockdown of ATM, ATR
and DNA-PK has a prolonged inhibition on mRNA levels. Figure S4: PremiR-145 induces expression
of miR-145.
Author Contributions: Conceptualization, K.E.P. and N.A.T.; methodology, K.E.H., K.R.-S., M.A.B.;
validation, K.E.H., K.R.-S. and M.A.B.; formal analysis, K.E.H. and K.R.-S.; investigation, K.E.H.,
Cells 2021, 10, 919 17 of 19
K.R.-S., M.A.B., N.A.T., K.E.P.; resources, D.J.O., K.E.P.; writing—original draft preparation, K.E.P.,
K.R.-S., N.A.T., K.E.H.; writing—review and editing, M.A.B., D.J.O.; supervision, K.E.P. and N.A.T.;
funding acquisition, K.E.P. and N.A.T. All authors have read and agreed to the published version of
the manuscript.
Funding: This research was funded by a Diabetes UK project grant (15/0005143) awarded to K.E.P.
and N.A.T.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Leeds West Research Ethics Committee of YORKSHIRE
& THE HUMBER (protocol code CA/01/040, 23/03/16).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the
study.
Data Availability Statement: Data are contained within the article and/or supplementary materials.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
References
1. Booth, G.L.; Kapral, M.K.; Fung, K.; Tu, J.V. Relation between age and cardiovascular disease in men and women with diabetes
compared with non-diabetic people: A population-based retrospective cohort study. Lancet 2006, 368, 29–36. [CrossRef]
2. Katsuumi, G.; Shimizu, I.; Yoshida, Y.; Minamino, T. Vascular Senescence in Cardiovascular and Metabolic Diseases. Front.
Cardiovasc. Med. 2018, 5, 18. [CrossRef] [PubMed]
3. Hakala, T.; Pitkänen, O.; Halonen, P.; Mustonen, J.; Turpeinen, A.; Hippelainen, M. Early and late outcome after coronary artery
bypass surgery in diabetic patients. Scand. Cardiovasc. J. 2005, 39, 177–181. [CrossRef]
4. Kubal, C.; Srinivasan, A.K.; Grayson, A.D.; Fabri, B.M.; Chalmers, J.A. Effect of Risk-Adjusted Diabetes on Mortality and
Morbidity After Coronary Artery Bypass Surgery. Ann. Thorac. Surg. 2005, 79, 1570–1576. [CrossRef] [PubMed]
5. Owens, C.D. Adaptive changes in autogenous vein grafts for arterial reconstruction: Clinical implications. J. Vasc. Surg. 2010, 51,
736–746. [CrossRef] [PubMed]
6. Madi, H.A.; Riches, K.; Warburton, P.; O’Regan, D.J.; Turner, N.A.; Porter, K.E. Inherent differences in morphology, proliferation,
and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am. J. Physiol. Cell
Physiol. 2009, 297, C1307–C1317. [CrossRef]
7. Riches, K.; Warburton, P.; O’Regan, D.J.; Turner, N.A.; Porter, K.E. Type 2 diabetes impairs venous, but not arterial smooth muscle
cell function: Possible role of differential RhoA activity. Cardiovasc. Revasc. Med. 2014, 15, 141–148. [CrossRef]
8. Riches, K.; Alshanwani, A.R.; Warburton, P.; O’Regan, D.J.; Ball, S.G.; Wood, I.C.; Turner, N.A.; Porter, K.E. Elevated expression
levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in
phenotype and function. J. Mol. Cell Cardiol. 2014, 74, 240–250. [CrossRef]
9. Hu, H.; Gatti, R.A. MicroRNAs: New players in the DNA damage response. J. Mol. Cell Biol. 2011, 3, 151–158. [CrossRef]
10. Ugalde, A.P.; Ramsay, A.J.; De La Rosa, J.; Varela, I.; Marinño, G.; Cadinñanos, J.; Lu, J.; Freije, J.M.P.; López-Otín, C. Aging and
chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J. 2011, 30, 2219–2232. [CrossRef]
11. Iaconetti, C.; De Rosa, S.; Polimeni, A.; Sorrentino, S.; Gareri, C.; Carino, A.; Sabatino, J.; Colangelo, M.; Curcio, A.; Indolfi, C.
Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc. Res.
2015, 107, 522–533. [CrossRef]
12. Santulli, G.; Wronska, A.; Uryu, K.; Diacovo, T.G.; Gao, M.; Marx, S.O.; Kitajewski, J.; Chilton, J.M.; Akat, K.M.; Tuschl, T.;
et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J. Clin. Investig. 2014, 124,
4102–4114. [CrossRef]
13. Torella, D.; Iaconetti, C.; Catalucci, D.; Ellison, G.M.; Leone, A.; Waring, C.D.; Bochicchio, A.; Vicinanza, C.; Aquila, I.; Curcio, A.;
et al. MicroRNA-133 Controls Vascular Smooth Muscle Cell Phenotypic Switch In Vitro and Vascular Remodeling In Vivo. Circ.
Res. 2011, 109, 880–893. [CrossRef] [PubMed]
14. Wang, Y.; Taniguchi, T. MicroRNAs and DNA damage response: Implications for cancer therapy. Cell Cycle 2013, 12, 32–42.
[CrossRef] [PubMed]
15. Porter, K.E.; Naik, J.; Turner, N.A.; Dickinson, T.; Thompson, M.M.; London, N.J. Simvastatin inhibits human saphenous vein
neointima formation via inhibition of smooth muscle cell proliferation and migration. J. Vasc. Surg. 2002, 36, 150–157. [CrossRef]
16. Riches, K.; Angelini, T.G.; Mudhar, G.S.; Kaye, J.; Clark, E.; Bailey, M.A.; Sohrabi, S.; Korossis, S.; Walker, P.G.; Scott, D.J.A.; et al.
Exploring smooth muscle phenotype and function in a bioreactor model of abdominal aortic aneurysm. J. Transl. Med. 2013, 11,
208. [CrossRef]
17. Turner, N.A.; Mughal, R.S.; Warburton, P.; O’Regan, D.J.; Ball, S.G.; Porter, K.E. Mechanism of TNFα-induced IL-1α, IL-1β and
IL-6 expression in human cardiac fibroblasts: Effects of statins and thiazolidinediones. Cardiovasc. Res. 2007, 76, 81–90. [CrossRef]
Cells 2021, 10, 919 18 of 19
18. Riches, K.; Clark, E.; Helliwell, R.J.; Angelini, T.G.; Hemmings, K.E.; Bailey, M.A.; Bridge, K.I.; Scott, D.J.A.; Porter, K.E.
Progressive Development of Aberrant Smooth Muscle Cell Phenotype in Abdominal Aortic Aneurysm Disease. J. Vasc. Res. 2017,
55, 35–46. [CrossRef] [PubMed]
19. Bennett, M.R.; Clarke, M.C.H. Killing the old: Cell senescence in atherosclerosis. Nat. Rev. Cardiol. 2017, 14, 8–9. [CrossRef]
[PubMed]
20. Freund, A.; Laberge, R.-M.; DeMaria, M.; Campisi, J. Lamin B1 loss is a senescence-associated biomarker. Mol. Biol. Cell 2012, 23,
2066–2075. [CrossRef] [PubMed]
21. Gurung, R.; Choong, A.M.; Woo, C.C.; Foo, R.; Sorokin, V. Genetic and Epigenetic Mechanisms Underlying Vascular Smooth
Muscle Cell Phenotypic Modulation in Abdominal Aortic Aneurysm. Int. J. Mol. Sci. 2020, 21, 6334. [CrossRef]
22. Riches, K.; Huntriss, J.; Keeble, C.; Wood, I.C.; O’Regan, D.J.; Turner, N.A.; Porter, K.E. Mapping the methylation status of the
miR-145 promoter in saphenous vein smooth muscle cells from individuals with type 2 diabetes. Diabetes Vasc. Dis. Res. 2017, 14,
122–129. [CrossRef]
23. Riches-Suman, K. Diverse roles of microRNA-145 in regulating smooth muscle (dys)function in health and disease. Biochem. Soc.
Trans. 2021, 49, 353–363. [CrossRef]
24. Pashaei, E.; Guzel, E.; Ozgurses, M.E.; Demirel, G.; Aydin, N.; Ozen, M. A Meta-Analysis: Identification of Common Mir-145
Target Genes that have Similar Behavior in Different GEO Datasets. PLoS ONE 2016, 11, e0161491. [CrossRef] [PubMed]
25. Suzuki, H.I.; Yamagata, K.; Sugimoto, K.; Iwamoto, T.; Kato, S.; Miyazono, K. Modulation of microRNA processing by p53. Nature
2009, 460, 529–533. [CrossRef] [PubMed]
26. Hooten, N.N.; Evans, M.K. Techniques to Induce and Quantify Cellular Senescence. J. Vis. Exp. 2017, 123, e55533. [CrossRef]
27. Chi, C.; Li, D.-J.; Jiang, Y.-J.; Tong, J.; Fu, H.; Wu, Y.-H.; Shen, F.-M. Vascular smooth muscle cell senescence and age-related
diseases: State of the art. Biochim. Biophys. Acta Mol. Basis Dis. 2019, 1865, 1810–1821. [CrossRef] [PubMed]
28. Bartoli-Leonard, F.; Wilkinson, F.L.; Schiro, A.; Inglott, F.S.; Alexander, M.Y.; Weston, R. Loss of SIRT1 in diabetes accelerates DNA
damage-induced vascular calcification. Cardiovasc. Res. 2021, 117, 836–849. [CrossRef] [PubMed]
29. Lin, X.; Yan, J.; Tang, D. ERK kinases modulate the activation of PI3 kinase related kinases (PIKKs) in DNA damage response.
Histol. Histopathol. 2013, 28, 1547–1554.
30. Job, A.; Schmitt, L.-M.; von Wenserski, L.; Lankat-Buttgereit, B.; Gress, T.M.; Buchholz, M.; Gallmeier, E. Inactivation of PRIM1
Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors. Neoplasia 2018, 20, 1135–1143. [CrossRef]
31. Malhas, A.; Saunders, N.J.; Vaux, D.J. The nuclear envelope can control gene expression and cell cycle progression via miRNA
regulation. Cell Cycle 2010, 9, 531–539. [CrossRef]
32. Cioce, M.; Ganci, F.; Canu, V.; Sacconi, A.; Mori, F.; Canino, C.; Korita, E.; Casini, B.; Alessandrini, G.; Cambria, A.; et al.
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 2013, 33, 5319–5331. [CrossRef] [PubMed]
33. Li, R.; Yan, G.; Zhang, Q.; Jiang, Y.; Sun, H.; Hu, Y.; Sun, J.; Xu, B. miR-145 inhibits isoproterenol-induced cardiomyocyte
hypertrophy by targeting the expression and localization of GATA6. FEBS Lett. 2013, 587, 1754–1761. [CrossRef] [PubMed]
34. Freund, A.; Patil, C.K.; Campisi, J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated
secretory phenotype. EMBO J. 2011, 30, 1536–1548. [CrossRef]
35. Malaquin, N.; Carrier-Leclerc, A.; Dessureault, M.; Rodier, F. DDR-mediated crosstalk between DNA-damaged cells and their
microenvironment. Front. Genet. 2015, 6, 94. [CrossRef] [PubMed]
36. Alspach, E.; Flanagan, K.C.; Luo, X.; Ruhland, M.K.; Huang, H.; Pazolli, E.; Donlin, M.J.; Marsh, T.; Piwnica-Worms, D.; Monahan,
J.; et al. p38MAPK Plays a Crucial Role in Stromal-Mediated Tumorigenesis. Cancer Discov. 2014, 4, 716–729. [CrossRef] [PubMed]
37. Farrokhnia, F.; Aplin, J.D.; Westwood, M.; Forbes, K. MicroRNA Regulation of Mitogenic Signaling Networks in the Human
Placenta. J. Biol. Chem. 2014, 289, 30404–30416. [CrossRef]
38. Hu, G.; Zhao, X.; Wang, C.; Geng, Y.; Zhao, J.; Xu, J.; Zuo, B.; Zhao, C.; Wang, C.; Zhang, X. MicroRNA-145 attenuates TNF-
alpha-driven cartilage matrix degradation in osteoarthritis via direct suppression of MKK4. Cell Death Dis. 2017, 8, e3140.
[CrossRef]
39. Long, X.; Miano, J.M. Transforming growth factor-beta1 (TGF-β1) utilizes distinct pathways for the transcriptional activation of
microRNA 143/145 in human coronary artery smooth muscle cells. J. Biol. Chem. 2011, 286, 30119–30129. [CrossRef]
40. O’Leary, L.; Sevinç, K.; Papazoglou, I.M.; Tildy, B.; Detillieux, K.; Halayko, A.J.; Chung, K.F.; Perry, M.M. Airway smooth muscle
inflammation is regulated by microRNA-145 in COPD. FEBS Lett. 2016, 590, 1324–1334. [CrossRef]
41. Hong, S.; Noh, H.; Chen, H.; Padia, R.; Pan, Z.K.; Su, S.-B.; Jing, Q.; Ding, H.-F.; Huang, S. Signaling by p38 MAPK Stimulates
Nuclear Localization of the Microprocessor Component p68 for Processing of Selected Primary MicroRNAs. Sci. Signal. 2013, 6,
ra16. [CrossRef]
42. Hu, B.; Wu, Z.; Jin, H.; Hashimoto, N.; Liu, T.; Phan, S.H. CCAAT/enhancer-binding protein β isoforms and the regulation of
α-smooth muscle actin gene expression by IL-1β. J. Immunol. 2004, 173, 4661–4668. [CrossRef]
43. Yin, Y.; Yan, Z.-P.; Lu, N.-N.; Xu, Q.; He, J.; Qian, X.; Yu, J.; Guan, X.; Jiang, B.-H.; Liu, L.-Z. Downregulation of miR-145 associated
with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochim. Biophys. Acta Bioenerg. 2013,
1829, 239–247. [CrossRef] [PubMed]
44. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J.P.; Sedivy, J.M.; Kinzler, K.W.; Vogelstein, B. Requirement for
p53 and p21 to Sustain G2 Arrest After DNA Damage. Science 1998, 282, 1497–1501. [CrossRef] [PubMed]
Cells 2021, 10, 919 19 of 19
45. Spizzo, R.; Nicoloso, M.S.; Lupini, L.; Lu, Y.; Fogarty, J.; Rossi, S.; Zagatti, B.; Fabbri, M.C.; Veronese, A.; Liu, X.; et al. miR-145
participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell
Death Differ. 2009, 17, 246–254. [CrossRef] [PubMed]
46. Hubackova, S.; Krejcikova, K.; Bartek, J.; Hodny, Z. IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response
are shared features of replicative, oncogene-induced, and drug-induced paracrine ‘Bystander senescence’. Aging 2012, 4, 932–951.
[CrossRef] [PubMed]
47. Sorokin, V.; Vickneson, K.; Kofidis, T.; Woo, C.C.; Lin, X.Y.; Foo, R.; Shanahan, C.M. Role of Vascular Smooth Muscle Cell Plasticity
and Interactions in Vessel Wall Inflammation. Front. Immunol. 2020, 11. [CrossRef] [PubMed]
48. Porter, K.E.; Varty, K.; Jones, L.; Bell, P.R.; London, N.J. Human saphenous vein organ culture: A useful model of intimal
hyperplasia? Eur. J. Vasc. Endovasc. Surg. 1996, 11, 48–58. [CrossRef]
